Buffalo shooting ignites a debate over the role of genetics researchers in white supremacist ideology
By Megan Molteni,
STAT
| 05. 23. 2022
Photo by Colin Lloyd on Unsplash
The 18-year-old gunman suspected of carrying out a racist attack that killed 10 and injured three people in Buffalo, N.Y., last weekend left no questions about why he drove 200 miles to a supermarket in a predominantly Black neighborhood and opened fire. A 180-page document he allegedly posted online detailed the white supremacist ideologies that motivated his plan to target and murder Black Americans.
But for the genetics researchers who discovered their work cited in the screed as justification for the bloodshed, there are only questions — how did this happen? Could we have done more to prevent it? And what needs to change to stop it from happening again?
“I’m horrified,” said Daniel Benjamin, a behavioral economist at the University of California, Los Angeles, and co-founder of the Social Science Genetic Association Consortium (SSGAC). Formed in 2011 and funded in part by the National Institutes of Health, the group aims to find links between genes and outcomes that interest social scientists. Beginning in 2013, they began to publish a series of bigger and...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...